Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: Analysis from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Trials - 06/08/11
, Jamil Dihu, MD c, Karl Swedberg, MD d, Sadiya Khan, MD e, Aldo P. Maggioni, MD f, Liliana Grinfeld, MD g, Faiez Zannad, MD h, John C. Burnett, MD i, John Ouyang, PhD j, James E. Udelson, MD k, Marvin A. Konstam, MD kRésumé |
Background |
A rapid and sustained relief of heart failure (HF) symptoms and signs is an important goal of management in patients hospitalized for acute HF syndromes (AHFS). To date, no novel therapy in AHFS have been shown to improve signs and symptoms throughout hospitalization. This study explores the clinical effects of tolvaptan, a vasopressin-2-receptor antagonist, in addition to standard medical therapies on physician-assessed signs and symptoms in hospitalized AHFS patients.
Methods |
The EVEREST trial randomized 4,133 patients admitted with worsening HF and reduced ejection fraction (≤40%) within 48 hours after hospital admission. On each inpatient day, investigators assessed dyspnea, orthopnea, fatigue, jugular venous distension (JVD), rales, and pedal edema by predefined ordinal scales. Responder analyses were performed for each sign and symptom, with significant clinical response defined as a change in one point on the measurement scale.
Results |
Post hoc analysis demonstrated greater likelihood of clinical improvement in physician-assessed dyspnea, edema, orthopnea, and JVD among tolvaptan-treated subjects (P < .05) as early as inpatient day 1. This difference was observed throughout hospitalization only for JVD and orthopnea through day 3.
Conclusion |
The addition of tolvaptan to standard therapy for AHFS improves physician-assessed signs and symptoms during hospitalization without serious adverse short- or long-term effects.
Le texte complet de cet article est disponible en PDF.Plan
Vol 161 - N° 6
P. 1067-1072 - juin 2011 Retour au numéro
Article précédent
- Site of latest activation in patients eligible for cardiac resynchronization therapy: Patterns of dyssynchrony among different QRS configurations and impact of heart failure etiology
- Rutger J. van Bommel, Claudia Ypenburg, Sjoerd A. Mollema, C. Jan Willem Borleffs, Victoria Delgado, Matteo Bertini, Nina Ajmone Marsan, Ernst E. van der Wall, Martin J. Schalij, Jeroen J. Bax
- Late gadolinium enhancement on cardiac magnetic resonance and phenotypic expression in hypertrophic cardiomyopathy
- Maria Rosa Conte, Sergio Bongioanni, Amedeo Chiribiri, Stefano Leuzzi, Elisabetta Lardone, Paolo Di Donna, Alfredo Pizzuti, Stefania Luceri, Federico Cesarani, Barbara Mabritto, Giuseppe Biondi Zoccai, Rodolfo Bonamini, Fiorenzo Gaita
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?